InflaRx Yönetim

Yönetim kriter kontrolleri 2/4

InflaRx CEO'su Niels Riedemann, Jan2007 tarihinde atandı, in görev süresi 17.83 yıldır. şirketin hisselerinin 1.82% doğrudan sahiptir ve bu hisselerin değeri MX$ 34.24M dir. Yönetim ekibinin ve yönetim kurulunun ortalama görev süresi sırasıyla 3.9 yıl ve 5.5 yıldır.

Anahtar bilgiler

Niels Riedemann

İcra Kurulu Başkanı

n/a

Toplam tazminat

CEO maaş yüzdesi	n/a
CEO görev süresi	17.8yrs
CEO sahipliği	1.8%
Yönetim ortalama görev süresi	3.9yrs
Yönetim Kurulu ortalama görev süresi	5.5yrs

Son yönetim güncellemeleri

Recent updates

CEO

Niels Riedemann (51 yo)

17.8yrs

Görev süresi

Prof. Dr. Niels C. Riedemann, M.D. is Chief Executive Officer of InflaRx N.V. since 2007 and serves as its Executive Director. Dr. Riedemann founded InflaRx N.V. in 2007 as InflaRx GmbH. Dr. Riedemann spen...

Liderlik Ekibi

İsim	Pozisyon	Görev süresi	Tazminat	Sahiplik
Niels Riedemann	Co-Founder	17.8yrs	Veri yok	1.82% MX$ 34.2m
Renfeng Guo	Co-Founder	17.8yrs	Veri yok	2.99% MX$ 56.5m
Thomas Taapken	Chief Financial Officer	4.1yrs	Veri yok	0.0059% MX$ 112.1k
Derval O'Carroll	Senior VP and Global Head of Regulatory Affairs & Compliance	1.6yrs	Veri yok	Veri yok
Camilla Chong	Chief Medical Officer	1.3yrs	Veri yok	Veri yok
Jan Medina	Head of Investor Relations & VP	less than a year	Veri yok	Veri yok
Christian Schmid	VP and Head of Legal Affairs & General Counsel	no data	Veri yok	Veri yok
Nicole Bertsch	Senior Director & Head of Human Resources	3.7yrs	Veri yok	Veri yok
Maria Habel	VP, Head of Preclinical R&D and QC	11.8yrs	Veri yok	Veri yok
Bruce Burnett	VP & Head of Medical Affairs	no data	Veri yok	Veri yok
Kofi Boaten	Senior Director and Head of Supply Quality & Clinical Trial Supplies	no data	Veri yok	Veri yok
Peter Hurt	Senior Director and Head of Drug Safety & Pharmacovigiliance	no data	Veri yok	Veri yok

3.9yrs

Ortalama Görev Süresi

56yo

Ortalama Yaş

Deneyimli Yönetim: IFRX N 'un yönetim ekibi deneyimli olarak değerlendirilmektedir (ortalama görev süresi 3.9 yıldır).

Yönetim Kurulu Üyeleri

İsim	Pozisyon	Görev süresi	Tazminat	Sahiplik
Niels Riedemann	Co-Founder	no data	Veri yok	1.82% MX$ 34.2m
Renfeng Guo	Co-Founder	no data	Veri yok	2.99% MX$ 56.5m
Nicolas Fulpius	Independent Chairman of the Board	17.8yrs	Veri yok	0.79% MX$ 15.0m
K. Reinhart	Member of Scientific Advisory Board	no data	Veri yok	Veri yok
P. Ward	Member of Scientific Advisory Board	no data	Veri yok	Veri yok
Richard Brudnick	Independent Non-Executive Director	5.5yrs	Veri yok	0.085% MX$ 1.6m
Hege Hellstrom	Non-Executive Director	1.6yrs	Veri yok	Veri yok
Mark Kubler	Independent Non-Executive Director	9.8yrs	Veri yok	1.63% MX$ 30.8m
Anthony Gibney	Independent Non-Executive Director	3.5yrs	Veri yok	0.017% MX$ 320.3k

5.5yrs

Ortalama Görev Süresi

53yo

Ortalama Yaş

Deneyimli Yönetim Kurulu: IFRX N 'nin yönetim kurulu üyeleri deneyimli olarak kabul edilir (ortalama görev süresi 5.5 yıldır).

InflaRx Yönetim

Yönetim kriter kontrolleri 2/4

Anahtar bilgiler

Son yönetim güncellemeleri

InflaRx N.V., Annual General Meeting, Apr 25, 2024

InflaRx N.V. Appoints Jan Medina as Head of Investor Relations

Inflarx N.V. Appoints Camilla Chong as Chief Medical Officer, Effective July 1, 2023

InflaRx N.V., Annual General Meeting, Apr 28, 2022

Recent updates

InflaRx N.V. Receives Positive CHMP Opinion for GOHIBIC® (Vilobelimab) for the Treatment of SARS-CoV-2-Induced Acute Respiratory Distress Syndrome

InflaRx N.V. to Report Q3, 2024 Results on Nov 08, 2024

New major risk - Financial position

InflaRx N.V. to Report Q2, 2024 Results on Aug 08, 2024

Inflarx’S Gohibic (Vilobelimab) Selected for First Barda-Sponsored Clinical Trial to Evaluate Novel Host-Directed Therapeutics for Acute Respiratory Distress Syndrome (Ards)

InflaRx N.V. Hosts R&D Event Highlighting the Promise of INF904

InflaRx N.V. to Report Q1, 2024 Results on May 08, 2024

InflaRx N.V., Annual General Meeting, Apr 25, 2024

No longer forecast to breakeven

InflaRx N.V. to Report Q4, 2023 Results on Mar 21, 2024

New minor risk - Profitability

InflaRx N.V. Appoints Jan Medina as Head of Investor Relations

InflaRx N.V. Announces First Patient Dosed in Phase III Trial with Vilobelimab in Pyoderma Gangrenosum

InflaRx N.V. Announces Positive Topline Results from the Single Ascending Dose (SAD) Phase I Study with C5aR Inhibitor INF904

Inflarx N.V.'S Marketing Authorization Application (Maa) for Vilobelimab for Treatment of Critically Ill Covid-19 Patients Under Review by European Medicines Agency (Ema)

Inflarx N.V. Appoints Camilla Chong as Chief Medical Officer, Effective July 1, 2023

InflaRx N.V. Announces Details Related to the Design of its Planned Phase III Study with Vilobelimab in Ulcerative PG

InflaRx N.V. Provides Update on Planned Phase Iii Study Design in Pyoderma Gangrenosum with Vilobelimab and Status of Its Eua Application in Critically Ill Covid-19 Patients

InflaRx N.V. announced that it expects to receive $2.5 million in funding from Staidson (Beijing) BioPharmaceuticals Co., Ltd.

InflaRx N.V. Initiates First-In-Human Study with Small Molecule C5ar Inhibitor Inf904

Inflarx Submits Request for Emergency Use Authorization to US FDA for Vilobelimab for Treatment of Critically III COVID-19 Patients

InflaRx N.V. Announces Vilobelimab Phase III Results in Critically Ill COVID-19 Patients Published in the Lancet Respiratory Medicine

InflaRx Announces Plans to Apply for Emergency Use Authorization from the US FDA for Vilobelimab for Treatment of Critically III COVID-19 Patients

No longer forecast to breakeven

InflaRx Receives U.S. Food and Drug Administration Fast Track Designation for Treatment of Ulcerative Pyoderma Gangrenosum

InflaRx N.V. Provides Development Update for Vilobelimab in Pyoderma Gangrenosum and Severe COVID-19

No longer forecast to breakeven

InflaRx N.V., Annual General Meeting, Apr 28, 2022

InflaRx N.V. Announces Encouraging Phase III Topline Results from PANAMO Trial of Vilobelimab in Severe COVID-19 Patients

InflaRx N.V. Reports That It Has Received an Advice Letter from the U.S. Food and Drug Administration Related to Its Phase Iii Program with Vilobelimab

InflaRx N.V. Reports Progress in Ongoing Phase II Clinical Trial with Vilobelimab in Cutaneous Squamous Cell Carcinoma

InflaRx N.V Announces New Pipeline Program – Oral C5aR Inhibitor

InflaRx N.V. Initiates Phase III Clinical Program with Vilobelimab in Hidradenitis Suppurativa

CEO

Görev süresi

Liderlik Ekibi

Ortalama Görev Süresi

Ortalama Yaş

Yönetim Kurulu Üyeleri

Ortalama Görev Süresi

Ortalama Yaş